Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 3 art units • 4 examiners • 1 of 6 (17%) have an AI response strategy ready • 2 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 2 (33%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKOKO III, JOHN JOSEPH | 2 | 53.1% | +58.2% |
| PUTTLITZ, KARL J | 2 | 69.1% | +18.6% |
| AULAKH, CHARANJIT | 1 | 80.6% | -14.5% |
| CUNNINGCHEN, KATHLEEN MARY | 1 | 61.1% | +62.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18715609 | METHOD FOR PREPARING DRUG-LINKER CONJUGATE | AULAKH, CHARANJIT | — |
| 18324511 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | PUTTLITZ, KARL J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998772 | ANTIBODY DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SKOKO III, JOHN JOSEPH | 27d |
| 18648187 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SKOKO III, JOHN JOSEPH | — |
| 18532359 | COMBINATION THERAPIES FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER | CUNNINGCHEN, KATHLEEN MARY | — |
| 18324511 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | PUTTLITZ, KARL J | — |
| 17471653 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | PUTTLITZ, KARL J | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1646 | 2 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18715609 | METHOD FOR PREPARING DRUG-LINKER CONJUGATE | AULAKH, CHARANJIT | 1621 | §102§103§112 | Non-Final OA | — | Pending | May 31, 2024 |
| 18648187 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SKOKO III, JOHN JOSEPH | 1643 | §112DP | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18532359 | COMBINATION THERAPIES FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER | CUNNINGCHEN, KATHLEEN MARY | — | §103§112DP | Non-Final OA | — | Pending | Dec 07, 2023 |
| 18324511 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | PUTTLITZ, KARL J | 1646 | §103§112 | Final Rejection | — | Pending | May 26, 2023 |
| 17998772 | ANTIBODY DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SKOKO III, JOHN JOSEPH | 1643 | DP | Final Rejection | 27d | AI Ready | Nov 14, 2022 |
| 17471653 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | PUTTLITZ, KARL J | 1646 | DP | Final Rejection | — | Pending | Sep 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial